A PIPELINE POWERED BY

A PIPELINE POWERED BYPASSION

circle

PUBLICATIONS

 

Cardiovascular

Teerlink JR, Felker GM, McMurray JV, Solomon SD, Adams KFA, Cleland JGF, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsanyi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. The Lancet. Epub November 30, 2016. Article

Teerlink JR, Felker G, McMurray JV, Solomon SD, Monsalvo ML, Johnston J, Malik FI, Honarpour N. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Improved Contractility and Evolution of Ventricular Remodelling Through Time. Heart Failure 2016. Florence, Italy. May 2016. Poster presentation

Teerlink JR, Felker G, McMurray JV, et al. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Journal of the American College of Cardiology, March 29, 2016. Article

Vu T, Ma P, Xiao JJ, Want YMC, Malik FI, Chow AT. Population Pharmacokinetic-Pharmacodynamic Modeling of Omecamtiv Mecarbil, a cardiac Myosin Activator, in Healthy Volunteers and Patients with Stable Heart Failure. Journal of Clinical Pharmacology, Epub 2015 May 6. Article

Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Failure, 2015;3(1):22-9. Epub 2014 Nov 11. Article

Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Ecandon RD, Elliott L, Bee R, Habiibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. Dose-dependent Augmentation of Cardiac Systolic Function with the Selective Cardiac Myosin Activator, Omecamtiv Mecarbil: a First-in-man Study. The Lancet, 2011;378:667-75. Article

Cleland JGF, Teerlink JR, Senior R, Nifontov EM, McMurray JJV, Lang C, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzbert M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. The Effects of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Cardiac Function in Systolic Heart Failure: a Double-blind, Placebo-controlled, Crossover, Dose-ranging Phase 2 Trial. The Lancet, 2011;378:676-83. Article

Malik FI, Morgan BP. Cardiac Myosin Activation Part 1: From Concept to Clinic. Journal of Molecular and Cellular Cardiology, 2011 October;51(4):454-461. Article

Malik FI, et al. Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure. Science, 2011 March;331;1439-1443. Article

Habibzadeh MR, Schiller NB, Malik FI, Chen MM, Saikali KG, Wolff AA, Goldman JH, Teerlink JR. Effect of the Selective Cardiac Myosin Activator, Omecamtiv Mecarbil, on Left Atrial Performance in Healthy Men. 2010 Heart Failure Society of America Annual Meeting (HFSA). San Diego, CA. September 2010. Poster presentation

Morgan BP, et al. Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin. ACS Medicinal Chemistry Letters, August 2010. Article

Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs with Systolic Heart Failure. Circulation Heart Failure, 2010 Jul;3(4):522-7. Epub 2010 May 24. Article

Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen MM, Malik F, Wolff AA, Shaburishvili T. Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina. 2009 Heart Failure Society of America Annual Meeting (HFSA), Boston, MA. September 2009. Poster presentation

Goldman JH, Teerlink JR, Saikali KG, Malik F, Wolff AA. Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452. 2009 Heart Failure Society of America Annual Meeting (HFSA), Boston, MA. September 2009. Poster presentation

Malik FI, Saikali KG, Chen MM, Lee JH, Goldman JH. An Analysis of the Response to CK-1827452, a Selective Cardiac Myosin Activator, in Stable Heart Failure Patients Stratified by Baseline Cardiac Function. 2009 Heart Failure Society of America Annual Meeting(HFSA), Boston, MA. September 2009. Poster presentation

Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen MM, Malik F, Wolff AA, Shaburishvili T. Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina. European Society of Cardiology (ESC) Congress 2009, Barcelona, Spain. August 2009. Poster presentation

Goldman JH, Teerlink JR, Saikali KG, Malik F, Wolff AA. Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452. European Society of Cardiology (ESC) Congress 2009, Barcelona, Spain. August 2009. Poster presentation

Goldman JH, Teerlink JR, Saikali KG, Malik F and Wolff AA. Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452. 2009 European Society of Cardiology, Heart Failure Congress, Nice, France. June 2009. Poster presentation

Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen MM, Malik F, Wolff AA, Shaburishvili T, and the CY 1221 Investigators. Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina. 2009 European Society of Cardiology, Heart Failure Congress, Nice, France. June 2009. Poster presentation

Senior R, Malik FI, Saikali KG, Lee JH, Chen MM, Brand G, Wolff AA, and the CY 1121 Investigators. The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in a Concentration-Dependent Manner in Patients with Stable Heart Failure. 2009 Annual American College of Cardiology (ACC), Orlando, FL. March 2009. Poster presentation

Teerlink John R. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Failure Reviews, February 21, 2009. Article and Link to Website

Parker JD, Michaels AD, Kass DA, Wolff AA, Felker GM and Malik FI. Rationale and Design for a Phase II Study Evaluating the Effect of the Cardiac Myosin Activator, CK-1827452, on Cardiac Function, Hemodynamics, and Myocardial Oxygen Consumption in Patients with Heart Failure. 2008 Annual Heart Failure Society of America (HFSA) Conference. Toronto, Ontario, Canada. September 2008. Poster presentation

Cleland JGF, et al. First Clinical Trial of the Selective Cardiac Myosin Activator, CK-1827452, in Heart Failure: Effect of Dose and Plasma Concentration on Systolic Function. European Society of Cardiology (ESC) Congress 2008. August, 2008. Poster presentation

Shen Y, Zhang Y, Morgans DJ, Vatner SF, Malik F. A Novel Inotropic Agent That Activates Cardiac Myosin and Increases Cardiac Contractility Without Increasing MVO2 in Heart Failure with Left Ventricular Hypertrophy. American College of Cardiology Conference, Chicago, IL. March, 2008. Poster presentation

Anderson RL, Pokrovskii M, Suekawa K, Rodriguez HM, Elias, KA. The Cardiac Myosin Activator CK-1827452-Induced Myocyte Contractility is Unchanged in the Presence of β-Blockade. 2007 American Society of Cell Biology (ASCB) Conference, Washington, DC. December, 2007. Poster presentation

Jerling M, Chew T, Escandon R, Lee J, Saikali K, Venables E, Clarke C, Malik F, Wolff A. Oral Bioavailability of the Selective Cardiac Myosin Activator CK-1827452: Chronic Oral Inotropic Therapy for Heart Failure. 2007 Annual Heart Failure Society of America Meeting, Washington, DC. September, 2007. Poster presentation

Malik FI, Saikali KG, Clarke CP, Teerlink JR, Wolff AA. Systolic Ejection Time Is a Sensitive Indicator of Left Ventricular Systolic Function During Treatment with the Selective Cardiac Myosin Activator, CK-1827452. 2007 Annual Heart Failure Society of America Meeting, Washington, DC. September, 2007. Poster presentation

Anderson R, Pokrovskii M, Elias K. Effects of Cardiac Myosin Activators on Excitation-Contraction (E-C) Coupling in Ventricular Myocytes. Biophysical Society 51st Annual Meeting, Baltimore, MD. March, 2007. Poster presentation

Rodriguez H, Kawas R, Malik F, Sakowicz R, Hartman J. The Cardiac Myosin Activator, CK-1827452, Accelerates the Enzymatic Step Gating Entry of Myosin into its Force Generating State. Biophysical Society 51st Annual Meeting, Baltimore, MD. March, 2007. Poster presentation

Anderson RL, Pokrovskii M, Elias KA. Effects of the Cardiac Myosin Activator CK-1316719 on Excitation-Contraction (E-C) Coupling in Ventricular Myocytes. 46th Annual American Society for Cell Biology Meeting, San Diego, CA. December, 2006. Poster presentation

Baliga R, Rodriguez HM, Guo D, Hartman JJ, Pierce DW, Sakowicz R, Morgan BP, Malik F, Finer JT. A Sensitive Assay for the Basal ATPase Activity of Cardiac Myosin. Society of Biomolecular Sciences Annual Meeting, Seattle (September 2006). Poster presentation

Anderson RL, Kawas RF, Pokrovskii MV, Godinez G, Lee KH, Mak J, Hartman JJ, Morgan BP, Morgans Jr., DJ, Malik F, Sakowicz R, Elias KA. Cardiac Myosin Activator CK-1316719 Increases Myofibril ATPase Activity and Myocyte Contractility in a Rat Model of Heart Failure. Heart Failure Society of America (HFSA), September, 2006. Poster presentation

Shen YT, Vatner SF, Morgans DJ, Malik F. Activating Cardiac Myosin, a Novel Inotropic Mechanism to Improve Cardiac Function in Conscious Dogs with Congestive Heart Failure. Heart Failure Society of America (HFSA), September, 2006. Poster presentation

Anderson RL, Sueoka SH, Lee KH, Rodriguez HM, Kawas R, Godinez G, Morgan BP, Sakowicz R, Morgans Jr, DJ, Malik F, Elias KA. In Vitro and In Vivo Characterization CK-1827452, a Selective Cardiac Myosin Activator. Heart Failure Society of America (HFSA), September, 2006. Poster presentation

Rodriguez HM, Sylvester S, Kawas R, Malik F, Sakowicz R. Activation of the Cardiac Sarcomere by a Small Molecule Agent, CK-1213296. Biophysical Society Annual Meeting. February, 2006. Poster presentation

Rodriguez HM, Sylvester S, Hartman J, Shen YT, Kass DA, Vatner SF, Malik F, Sakowicz R. A Detailed Kinetic Analysis of the Cardiac Myosin Activator, CK-1213296, Suggests It Improves Cardiac Contractility by Accelerating Transition from the Weak to Strongly Bound States. Molecular Mechanisms of Cardiac Disease and Regeneration. February, 2006. Poster presentation

Lenzi D, Fritsch A, Alexander G, Hansen R, Cong G, Zink W, Godinez G, Pham A, Trautman J, Pierce DW, Malik F, Finer JT. A Multiplexed and Automated Imaging Assay of Cardiac Myocyte Contractility. American Society of Cell Biology (ASCB) December, 2005. Poster presentation

Anderson RL, Sueoka SH, Rodriguez HM, Lee KH, Cox DR, Kawas R, Morgan BP, Sakowicz R, Morgans Jr DJ, Malik F, Elias KA. In Vitro and In Vivo Efficacy of the Cardiac Myosin Activator CK-1827452. American Society of Cell Biology (ASCB) December, 2005. Poster presentation

Malik F, Elias KA, Finer JT, Morgan BP, Sakowicz R, Anderson R, Baliga R, Conn L, Cox D, Garard M, Hartman J, Irvine J, Kawas R, Kraynack E, Kuklov A, Lee KH, Lu P, Muci A, Pierce DW, Rodriguez H, Suehiro I, Sueoka SH, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, and Morgans DJ . Direct Activation of Cardiac Myosin by CK-1827452 Improves Cardiac Function in a Dog Heart Failure Model. Heart Failure Society of America Meeting, September 2005. Poster presentation

Malik F, Shen Y, Katori T, Sueoka SH, Anderson R, Cox D, Garard M, Hartman J, Kim S, Kraynack E, Kuklov A, Lee KH, Lu P, Muci A, Niu C, Rodriguez H, Suehiro I, Sylvester S, Tochimoto T, Elias KA, Morgan BP, Sakowicz R, Kass DA, Vatner SF, Morgans DJ. Direct Activation of Cardiac Myosin, A Novel Mechanism for Improving Cardiac Function. American Heart Association (AHA) Keystone, July 2005. Poster presentation

Anderson R, Niu C, Elias K. The Cardiac Myosin Activator, CK-1122534, Overcomes the Myosin II Inhibitors 2, 3-Butanedione-2-Monoxime and (-)-S-Blebbistatin without Affecting the Ca2+ Transient in Ventricular Myocytes. American Society of Cell Biology, December 2004. Poster presentation

Niu C, Anderson R, Cox D, Qian X, Morgan B, Malik F, Morgans Jr D, Elias K. The Cardiac Myosin Activator, CK-1122534, Increases Contractility in Adult Cardiac Myocytes without Altering the Calcium Transient. American Society of Cell Biology, December 2004. Poster presentation

Niu C, Cox D, Lee K, Sylvester S, Sueoka S, Qian X, Feng B, Malik F, Morgans Jr D, Hartman J, Sakowicz R, Elias K. Cellular Responses of the Myosin Activator CK-0689705 in Normal and Heart Failure Models. American Society of Cell Biology, December 2004. Poster presentation

Rodriguez H, Sylvester S, Qian X, Morgan B, Morgans Jr D, Malik F, Sakowicz R. Activation of Cardiac Sarcomere ATPase by CK-1122534, a Small Molecule Agent that Specifically Targets Cardiac Myosin. American Society of Cell Biology, December 2004. Poster presentation

Rodriguez H, Sylvester S, Sakowicz R. Interaction of Myosin with Blebbistatin Reported by Fluorescence Spectroscopy. American Society of Cell Biology, December 2004. Poster presentation

Niu C, Anderson RL, Cox DR, Morgan BP, Morgans Jr DJ, Malik F, Elias KA. The Cardiac Myosin Activator, CK1122534, Increases Contractility in Adult Cardiac Myocytes But Does Not Affect the Transient or Depend on Second Messenger Signaling. American Heart Association, November 2004. Poster presentation

Skeletal

Hwee DT, DiDonato CJ, Malik FI, Chin ER. The Fast Skeletal Troponin Activator, CK-2127107, Improves Muscle Function in Mouse Models of Spinal Muscular Atrophy. 2017 MDA Scientific Conference. Arlington, VA, March 2017. Poster Presentation

Jahandideh S, Taylor AA, Bian A, Meng L, Beaulieu D, Keymer M, Andrews J, Ennist DL. Machine Learning Model for the Prediction of Slow Vital Capacity. 27th International Symposium on ALS/MND. Dublin, Ireland, December 2016. Poster presentation

Heiman-Patterson T, Andrews JA, Cudkowicz M, de Carvalho M, Genge A, Hardiman O, Jackson C, Kulke S, Lechtzin N, Mitsumoto H, Rudnicki SA, Silani V, van den Berg LH. Understanding the Use of Noninvasive Ventilation in the Treatment of Amyotrophic Lateral Sclerosis: Results of an International Physician Survey. 27th International Symposium on ALS/MND. Dublin, Ireland, December 2016. Poster presentation

Pinto S, de Carvalho M. Correlation between Forced Vital Capacity and Slow Vital Capacity for the assessment of respiratory involvement in Amyotrophic Lateral Sclerosis: a prospective study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2016 Dec 2:1-6. Article

Rudnicki SA, Andrews JA, Malik FI, Wolff AA, Day JW. CK-2127107, a Selective Activator of the Fast Skeletal Muscle Troponin Complex, for the Potential Treatment of Spinal Muscular Atrophy. 2016 Annual SMA Conference. Orlando, FL, June 2016. Poster presentation

Shefner JM, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Andrews JA. Decline in Slow Vital Capacity Predicts Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death. American Academy of Neurology 2016. Vancouver, BC, Canada, April 2016. Poster presentation

Andrews JA, Wolff AA, Lee J, Barragan D, Meng L, Bian A, Malik FI, Shefner JM. Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices of Treatment for a Year in ALS (VITALITY-ALS): Study Design of a Phase III Clinical Trial of Tirasemtiv in ALS. 2016 MDA Clinical Conference. Arlington, VA, March 2016. Poster presentation

Shefner JM, Meng L, Kulke SF, Rudnicki S, Wolff AA, Bozik ME, Malik FI, Andrews JA. Decline in Slow Vital Capacity Predicts Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death. 2016 MDA Clinical Conference. Arlington, VA, March 2016. Poster presentation

Rudnicki S, Andrews JA, Malik FI, Wolff AA, Day JW. CK-2127107, a Selective Activator of the Fast Skeletal Muscle Troponin Complex, for the Potential Treatment of Spinal Muscular Atrophy. 2016 MDA Clinical Conference. Arlington, VA, March 2016. Poster presentation

Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews JA. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, epub March 16, 2016. Article

Andrews, JA, Meng L, Kulke SF, Rudnicki S, Wolff AA, Bozik ME, Malik FI, Shefner JM. Decline in Slow Vital Capacity Predicts Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy or Death. 6th Annual California ALS Research Summit, La Jolla, CA, January 2016. Poster presentation

Andrews J, Vijaykumar V, James J, Lee J, Miller T, Bian A, Meng L, Malik F, Wolff A. Pharmacokinetics and Pharmacodynamics of the Selective Fast Skeletal Muscle Troponin Activator, CK-2127107. 19th Annual SMA Researcher Meeting, June 2015. Poster presentation

Hwee DT, Kennedy AR, Hartman JJ, Ryans J, Durham N, Malik FI, Jasper JR. The Small Molecule Fast Skeletal Troponin Activator, CK-2127107, Improves Exercise Tolerance in a Rat Model of Heart Failure. Journal of Pharmacology and Experimental Therapeutics, epub February 12, 2015. Article

Hwee DT, Kennedy A, Malik FI, Jasper JR. Effect of Tirasemtiv on Submaximal Rodent Diaphragm Strength and Respiratory Function. 25th International Symposium on ALS/MND, Brussels, Belgium, December 2014. Poster presentation

Hwee DT, Kim L, Reedich E, Arnold WD, Kuntz NL, DiDonato CJ, Malik FI, Jasper JR. Fast Skeletal Muscle Troponin Activator Tirasemtiv Increases Muscle Function and Performance in Mouse Models of Spinal Muscular Atrophy. 25th International Symposium on ALS/MND, Brussels, Belgium, December 2014. Poster presentation

Meng L, Jordan S, Bian A, Andrews J, Shefner J, Wolff A, Blumen H, Iwasaki K, Pyenson B. Profile of Medical Care Costs in Patients with Amyotrophic Lateral Sclerosis in the Medicare Program and Under Commercial Insurance. 25th International Symposium on ALS/MND, Brussels, Belgium, December 2014. Poster presentation

Shefner J, Andrews J, Meng L, Bian Am, Wolff AA, the BENEFIT-ALS Study Group. Relationships Between Rilluzole and Tirasemtiv Levels on Outcomes in the BENEFIT-ALS Trial. 25th International Symposium on ALS/MND, Brussels, Belgium, December 2014. Poster presentation

Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik FI. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle and Nerve, December 2014. Article

Shefner JM, Wolff AA, Meng LL, Lee JH, James J, Andrews JA for the BENEFIT-ALS Study Group. Novel Data from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in Amyotrophic Lateral Sclerosis): Effects of Tirasemtiv Across Subgroups. 13th International Congress on Neuromuscular Diseases, Nice, France, July 2014. Poster presentation

Hwee DT, Kim LH, Chzastowski C, Arnold WD, Kuntz N, DiDonato CJ, Malik FI, Jasper JR. Tirasemtiv Increases Skeletal Muscle Performance in SMA Mice. 2014 Annual Spinal Muscle Atrophy Conference. National Harbor, MD, June 2014. Poster presentation

Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik FI, Hiatt WR. Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vascular Medicine, May 28, 2014. Article

Hwee DT, Kenedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik FI, Jasper JR. Fast Skeletal Muscle Troponin Activator Tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model. PLOS One, May 7, 2014. Article

Hooijman PE, Beishuizen A, de Waard MC, de Man FS, Vermeijden JW, Steenvoorde P, Bouwman RA, Lommen W, van Hees HW, Heunks LM, Dickhoff C, van der Peet DL, Girbes AR, Jasper JR, Malik FI, Stienen GJ, Hartemink KJ, Paul MA, Ottenheijm CA. Diaphragm fiber strength is reduced in critically ill patients and restored by a troponin activator. American Journal of Respiratory and Critical Care Medicine, April 1, 2014. Article

Malik FI, Hwee DT, Kennedy A, Ryans J, Jasper JR. The Fast Skeletal Muscle Troponin Activator Tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93a ALS Mouse Model. American Academy of Neurology. Philadelphia, PA, April 2014. Poster presentation

Hansen R, Saikali KG, Chou W, Russell A, Chen M, Vijayakumar V, Stoltz R, Baudry S, Enoka R, Morgans D, Wolff AA, Malik FI. Tirasemtiv, a Novel Activator of Fast Skeletal Muscle, Increases Isometric Force Evoked by Electrical Stimulation of the Anterior Tibialis Muscle in Healthy Male Subjects. American Academy of Neurology. Philadelphia, PA, April 2014. Poster presentation

Meng L, Jordan S, Bian A, Andrews J, Shefner J, Wolff A, Blumen H, Iwasaki K, Pyenson B. Profile of Medical Care Costs in Patients with Amyotrophic Lateral Sclerosis in the Medicare Program and Under Commercial Insurance. American Academy of Neurology. Philadelphia, PA, April 2014. Poster presentation

Hoojiman PE, Beishuizen A, de Waard MC, de Man FS, Vermeijden JW, Steenvoorde P, Bouwman RA, Lommen W, van Hees HWH, Heunks LMA, Dickhoff C, van der Peet DL, Girbes ARJ, Jasper JR, Malik FI, Stienen GJM, Hartemink KJ, Paul MA, Ottenheijm CAC. Diaphragm Fiber Strength Is Reduced in Critically Ill Patients and Restored by a Troponin Activator. Respiratory and Critical Care Medicine, April 2014. Article

Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz, RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik FI. Tirasemtiv Amplifies Skeletal Muscle Response to Nerve Activation in Humans. Muscle & Nerve, Online publication March 13,2014. Article

Andrews, JA. Tirasemtiv (CK-2017357): A Fast Skeletal Muscle Troponin Activator for the Potential Treatment of ALS. MDA Clinical Conference. Washington, DC, March 2014. Poster presentation

Shefner JM, Watson ML, Meng L, Wolff AA. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, August 2013, published online. Article

Shefner JM, Wolff AA, Meng L. The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, August 2013, published online. Article

Kennedy AR, Hwee D, Ryans J, Heald N, Ardiana A, Pakdel A, Malik FI, Jasper JR. CK-2127107 Improves Muscle Function and Exercise Capacity in a Rat Heart Failure Model. 2013 Keystone Symposium on Molecular and Cellular Biology Snowbird, UT. April 2013. Poster Presentation

Andrews J for the BENEFIT-ALS Investigator Group. Tirasemtiv (CK-2017357): A Selective Fast Skeletal Muscle Troponin Activator for the Potential Treatment of ALS. MDA Scientific Conference. Washington, DC. April 2013. Poster Presentation

Sanders DB, Rosenfeld J, Dimachkie M, Meng L, Malik FI. A Study to Evaluate Efficacy, Safety and Tolerability of Single Doses of Tirasemtiv in Patients with Myasthenia Gravis. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 2013 Poster presentation.

Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik FI, Wolff AA. Safety, Tolerability and Pharmacodynamics of a Skeletal Muscle Activator in Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis, May 2012, published online. Article

Shefner J, Andrews J, Bedlack R, Berry J, Goslin K, Jackson C, Kissel J, Lange D, Licht J, Mozaffar T, Pestronk A, Rosenfeld J, Wolff A, Lee J, Masonek J, Jones D, Meng L, Cedarbaum J. A Study to Evaluate Safety and Tolerability of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis Using a Twice-Daily, Dose-Titration Regimen. American Academy of Neurology 64th Annual Meeting in New Orleans, LA, April 2012. Poster presentation

Malik F, Russell AJ, Pannirselvam M, Hinken AC, Thomsen K, Ardiana A, Godinez G, Jia Z, Saikali KG, Chen MM, Morgans DJ, Jasper JR. The Fast Skeletal Troponin Activator, CK-2017357, Increases Muscle Function and Survival in SOD1 (G93A) Mice; a Model of ALS. American Academy of Neurology 64th Annual Meeting in New Orleans, LA, April 2012. Poster presentation

Kennedy AR, Heald N, Pakdel A, Ryans J, Russell AJ, Musch T, Poole D, Hageman S, Copp S, Malik FI, Jasper JR. The Fast Skeletal Troponin Activator, CK-2017357, Improves Resistance to Fatigue in Healthy, Conscious Rats. 2012 Experimental Biology Annual Conference in San Diego, CA, April 2012. Poster presentation

Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne WF, Chen MM, Clarke D, Collibee SE, Garard M, Hansen R, Jia Z, Lu P, Rodriguez H, Saikali KG, Schaletzky J, Vijayakumar V, Albertus DL, Claflin DR, Morgans DJ, Morgan BP, Malik FI. Activation of Fast Skeletal Muscle Troponin as a Potential Therapeutic Approach for Treating Neuromuscular Diseases.Nature Medicine, 2012;18:3:452-455. Article

Cedarbaum JM, Mitsumoto H, Pestronk A, Ringel S, Florence J, Sanjak M, Brooks BR. The ALSFRS @ 20: Evolution of the ALSFRS-R History, Clinimetric Properties and Future Directions. 22nd International Symposium on ALS/MND, Sydney, Australia, November 2011. Poster presentation

Shefner J, Brooks BR, Simmons Z, Mitsumoto H, Wolff AA, Lee JH, Jones DS, Mao J, Meng L, Cedarbaum JM, The CY 4024 Investigator Group. A Study to Evaluate Safety, Tolerability and Clinical Outcomes Following Repeated Doses of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis. 22nd International Symposium on ALS/MND, Sydney, Australia, November 2011. Poster presentation

Hiatt WR, Hirsch AT, Bauer TA, Malik F, Lee J, Lin Y, Han FX, Chen MM, Jones D, Cedarbaum JM, Wolff AA. Efficacy and Tolerability of the Novel Fast Skeletal Muscle Troponin Activator, CK-2017357, in Patients with Claudication. 22nd Annual Sessions of the Society for Vascular Medicine. Boston, MA, June 2011 Poster presentation

Bauer TA, Hirsch AT, Malik F, Wolff AA, Hiatt WR. Bilateral Concentric Heel Raise Test: A Novel Functional Endpoint for Early Stage Clinical Trials in Peripheral Artery Disease (PAD). 22nd Annual Sessions of the Society for Vascular Medicine. Boston, MA, June 2011 Poster presentation

Hinken A, Driscoll L, Godinez G, Lee K, Pannirselvan M, Hartman JJ, Muci AR, Morgans DJ, Morgan BP, Russell AJ, Jasper J, Malik FA. A Novel Fast Skeletal Muscle Activator, CK-2017357, Improves Muscle Function in a Rodent Model of Myasthenia Gravis. 2011 Experimental Biology Conference, Washington, DC. April 2011. Poster presentation

Hansen R, Saikali KG, Chou W, Russell A, Chen M, Vijayakumar V, Stoltz R, Baudry S, Enoka R, Morgans D, Wolff AA, Malik F. CK-2017357, a Novel Activator of Fast Skeletal Muscle, Increases Isometric Force Evoked by Electrical Stimulation of the Anterior Tibialis Muscle in Healthy Male Subjects. Society for Neuroscience 40th Annual Meeting: Neuroscience 2010. November 2010. Poster presentation

Mao J, Vo CH, Xu D, Bergnes G, Morgan BP, Morgans DJ. Cross-Species Pharmacokinetics of CK-2017357, a Novel Activator of the Fast Skeletal Sarcomere. 2010 FIP PSWC/AAPS Annual Meeting and Exposition. New Orleans, LA. November 2010. Poster presentation

Hinken AC, Driscoll L, Lee K, Hartman JJ, Marquez D, Hansen R, Muci A, Morgan B, Morgans DJ, Russell AJ, Malik FI. The Fast Skeletal Troponin Activator, CK-2017357, Reduces Muscle Fatigue in an in situ Model of Vascular Insufficiency. 2010 Annual Aging Muscle Symposium, San Francisco, California. September 2010. Poster presentation

Mao J, Chou W, Malik F, Lee J, Gabus C, Seroogy J, Saikali K, Morgans D, Wolff A. Oral Pharmacokinetics of CK-2017357 in Healthy Subjects. 39th Annual Meeting of the College of Clinical Pharmacology (ACCP.) Baltimore, MD. September 2010. Poster presentation

Chou W, Hansen R, Saikali KG, Russell A, Chen MM, Vijayakumar V, Stoltz R, Baudry S, Enoka R, Morgans D, Wolff AA, Malik F. CK-2017357, a Novel Activator of Fast Skeletal Muscle, Increases Isometric Force Evoked by Electrical Stimulation of the Anterior Tibialis Muscle in Healthy Male Subjects. XII International Congress on Neuromuscular Diseases, Naples, Italy. July 2010. Poster presentation

Hinken AC, Driscoll L, Lee K, Hartman JJ, Marquez D, Hansen R, Muci A, Morgan B, Morgans DJ, Russell AJ, Hansen R, Malik FI. The Fast Skeletal Troponin Activator, CK-2017357, Reduces Muscle Fatigue in an in situ Model of Vascular Insufficiency. Society for Vascular Medicine’s 2010 Annual Meeting: 21st Annual Scientific Sessions, Cleveland, OH. April 2010. Poster presentation

Hinken AC, Driscoll LC, Lee K, Hartman JJ, Marquez D, Hansen R, Muci A, Morgan B, Malik F, Russell AJ. Fast Skeletal Troponin Activator, CK-1909178, Reduces Muscle Fatigue in a Model of Peripheral Artery Disease in situ. Biophysical Society 54th Annual Meeting,San Francisco, CA. February 2010. Poster presentation

Kawas R, Russeel A, Muci A, Morgan B, Malik F, Hartman J. The Small Molecule Skeletal Sarcomere Activator, CK-2017357, is a Calcium Sensitizer that Binds Selectively to the Fast Skeletal Troponin Complex. Biophysical Society 54th Annual Meeting, San Francisco, CA. February 2010. Poster presentation

Russell AJ, Lee K, Hartman JJ, Marquez D, Hansen R, Muci A, Morgan B, Jia Z, Morgans DJ, Malik F. The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force and Reduces Muscle Fatigue in vitro and in situ. 5th Cachexia Conference, Barcelona, Spain. December 2009. Poster presentation

Russell AJ, Lee K, Jia Z, Muci A, Browne W, Tomlinson M, Hartman JJ, Hansen R, Hinken AC, Albertus D, Claflin D, Morgans DJ., Morgan B, Malik F. The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force in vitro and in situ. 2009 Experimental Biology Conference, New Orleans, LA. April 2009. Poster presentation

Lee K, Hartman J, Hansen R, Clarke D, Hinken A, Muci A, Morgan B, Vijayakumar V, Jia Z, Malik F, Russell A. The Fast Skeletal Troponin Activator, CK-1909178, Increases Skeletal Muscle Force in-vitro and in-situ. Biophysical Society 53rd Annual Meeting, Boston, MA. March 2009. Poster presentation

Kawas R, Russell A, Rodriguez H, Suekawa K, Muci A, Morgan B, Malik F, Hartman J. The Small Molecule Skeletal Sarcomere Activator, CK-1909178, is a Calcium Sensitizer that Binds Selectively to the Fast Skeletal Troponin Complex. Biophysical Society 53rd Annual Meeting. Boston, MA. March 2009. Poster presentation

Marquez D, Tomlinson M, Lievers J, Hartman J, Russell A, Hansen R. An Automated Apparatus for Isometric Force Analysis of Skinned Muscle Fibers. Biophysical Society 53rd Annual Meeting. Boston, MA. March 2009. Poster presentation

Additional Research

Sirigua S, Hartman JJ, Planelles-Herreroa VJ, Ropars V, Clancy S, Wang X, Chuang G , Qian X, Lu P, Barrett E, Rudolph K, Royer C, Morgan BP, Stura EA, Malik FI, Houdusse AM. Highly Selective Inhibition of Myosin Motors Provides the Basis of Potential Therapeutic Application. PNAS 2016; published ahead of print November 4, 2016, doi:10.1073/pnas.1609342113. Article

Ho D, Chen L, Zhao X, Durham N, Pannirselvam M, Vatner DE, Morgans DJ, Malik FI, Vatner SF, Shen YT. Smooth Muscle Myosin Inhibition: A Novel Therapeutic Approach for Pulmonary Hypertension. PLoS One. Published online May 2012 Article

Zhao X, Ho D, Abrazua P, Dhar SK, Wang X, Jia Z, Pannirselvam M, Morgand DJ, Malik FI, Vatner SF. Inhibition of Smooth Muscle Myosin as a Novel Therapeutic Target for Hypertension. The Journal of Pharmacology and Experimental Therapeutics, 2011 Oct;339(1):307-12. Epub 2011 Jul 22.Article

Pannirselvam M, Jia Z, Durham N, Godinez G, Zavodovskaya M, Lenzi D, Clancy S, Hartman JJ, Morgans DJ, Morgan BP, Qian X, Malik FI. The Direct Smooth Muscle Myosin Inhibitor, CK-2125927, Represents a Novel Therapeutic Mechanism of Bronchodilation. 2011 Experimental Biology Conference, Washington, DC. April 2011. Poster presentation

Zhiheng Jia, Guillermo Godinez, Nickie Durham, Xi Wang, Chihyuan Chuang, Pu-Ping Lu, Wenyue Wang, Bing Yao, Jeffrey Warrington, Sheila Clancy, James J Hartman, David J Morgans Jr, Bradley P Morgan, Xiangping Qian, Fady I Malik, Malar Pannirselvam. The Direct Smooth Muscle Myosin Inhibitor, CK-2018571, Represents a Novel Therapeutic Mechanism for Bronchodilation. American Thoracic Society’s 2010 International Conference, May 2010, New Orleans, LA. Poster presentation

Sheila Clancy, Zhiheng Jia , Malar Pannirselvam, Xiangping Qian, Bradley Morgan, Fady Malik, Jim Hartman. The Small Molecule Smooth Muscle Myosin Inhibitor, CK-2018571, Selectively Inhibits ATP Hydrolysis and Relaxes Smooth Muscle in vitro. Biophysical Society 54th Annual Meeting,San Francisco, CA. February 2010. Poster presentation

David Ho, Xin Zhao, Li Chen, You-Tang Shen, Xiangping Qian, David J. Morgans, Stephen F. Vatner, Fady I. Malik. Inhibition of Smooth Muscle Myosin, a Novel Therapeutic Approach for Pulmonary Hypertension. American Heart Association (AHA) 2009 Scientific Sessions. Orlando, FL. November 2009. Poster presentation

Qian X, Wang X, Hartman JJ, Jia Z, Clancy S, Yao B, Chuang C, Lu P, Pannirselvam M, Morgans DJ, Morgan BP, Malik FI. A Direct Inhibitor of Smooth Muscle Myosin as a Novel Therapeutic Approach for the Treatment of Systemic Hypertension. American Society of Hypertension 24th Annual Scientific Meeting and Exposition. San Francisco, CA. May 2009. Poster presentation